CNE0000009T3
CNE0000009T3
HARBIN PHARMACEUTICAL GROUP CO
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|
Market & Enterprise Value | |||
Market Cap | 18.61B EUR | 8.87B EUR | 8.69B EUR |
Enterprise Value | 17.31B EUR | 6.9B EUR | 6.5B EUR |
Valuation Multiples | |||
Trailing P/E | 36.95x | 36.8x | 29.68x |
Forward P/E | 24.63x | -- | -- |
Price to Sales | 1.15x | 0.73x | 0.72x |
Price to Book | 3.05x | 1.51x | 1.53x |
EV/Revenue | 1.07x | 0.57x | 0.54x |
EV/EBITDA | 19.57x | 13.59x | 11.47x |
Price to FCF (P/FCF) | 58.08x | 11.2x | 16.89x |
EV/FCF | 54.03x | 8.72x | 12.63x |
FCF Yield | 1.72% | 8.93% | 5.92% |